

July 2, 2021

The BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai - 400 001

Scrip Code: 541540

The National Stock Exchange of India

Limited Exchange Plaza, Bandra-Kurla
Complex Sandra (E), Mumbai - 400 051

Scrip Code: SOLARA

Dear Sir/ Madam,

**Sub: Press release - Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)
Regulation, 2015**

Please find attached press release issued by the Company titled:

“Restoration of CEP for Ranitidine Hydrochloride Drug Substance granted by EDQM”

Thanking you,

Yours Truly,

For Solara Active Pharma Sciences Limited



S. Murali Krishna
Company Secretary

Restoration of CEP for Ranitidine Hydrochloride Drug Substance granted by EDQM

- » **Solara is the first company to have its CEP restored among Ranitidine API manufacturers**
- » **Validation of Solara's strong quality systems and robust actions taken in response to emerging regulatory requirements**

Bangalore, India – July 2, 2021: Solara is pleased to announce that the CEP for Ranitidine Hydrochloride drug substance (CEP 2001-228) has been restored by EDQM. A revised CEP has been granted as of 01st July 2021. Ranitidine Hydrochloride was an important product for Solara and was manufactured at its Cuddalore site.

Solara had put in place robust manufacturing and quality processes to mitigate the risks of N-Nitroso Dimethylamine (NDMA) formation in the Ranitidine HCL API. Subsequent submission of the pertinent data has fast-tracked the restoration of CEP by EDQM. Solara is currently the only company among Ranitidine API manufacturers to have its CEP restored.

About Solara Active Pharma Sciences Limited:

Solara Active Pharma Sciences is a young, dynamic, entrepreneurial and customer-oriented API manufacturer. It has a legacy of over three decades and trace its origins to the API expertise of Strides Shasun Ltd. and the technical know-how of human API business from Sequent Scientific Ltd.

It aims at delivering value-based products while maintaining focus on customer needs. It has 140+ scientists working at two R&D centers and 6 API manufacturing facilities armed with global approvals and 2 dedicated R&D facilities. It stands by its vision to respect our partners by maintaining Integrity and operational transparency, which we intend to achieve through developing utmost efficiency across the organization.

Investor / Analyst contact

Abhishek Singhal

✉ abhishek.singhal@solara.co.in

☎ +91 99877 66968

Statutory and corporate affairs

Murali Krishna S

Raghavan. V

✉ investors@solara.co.in

☎ +91 44 4344 6700

Disclaimer: Certain statements in this document that are not historical facts and are forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Solara Active Pharma Sciences Ltd will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.